Entering text into the input field will update the search result below

Boston Scientific in partnership with Truveta on patient outcomes to improve care

Sep. 27, 2022 11:25 AM ETBoston Scientific Corporation (BSX) StockBy: Jonathan Block, SA News Editor

Boston Scientific Offers To Buy Guidant For $25 Billion

Joe Raedle/Getty Images News

  • Boston Scientific (NYSE:BSX) has entered into a collaboration with Truveta, which provides de-identified health data on more than 65M patients, to analyze patient outcomes related to the use of the device company's products.
  • The first analysis under the partnership will be on patient outcomes related to the use of Boston Scientific (BSX) products indicated for treatment of peripheral artery disease.
  • The company noted that the data provided by Truveta will help address the disparities in access to healthcare treatments.
  • Seeking Alpha's Quant Rating views Boston Scientific as a hold with high grades for profitability and momentum.

Recommended For You

More Trending News

About BSX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BSX--
Boston Scientific Corporation